États financiers détaillés de Ligand Pharmaceuticals Incorporated (LGND): compte de résultat, bilan et tableau de flux de trésorerie. Suivez l'évolution des marges, de la dette, de la liquidité et de la rentabilité d'une année sur l'autre avec jusqu'à 20 ans d'historique.
Résumé de l'Analyse
Ligand Pharmaceuticals Incorporated a enregistré un chiffre d'affaires de $268.1M sur le dernier exercice, avec un CAGR sur 5 ans de 10.4%.
Marges des 12 derniers mois: marge brute 98.6%, marge opérationnelle 34.7%, marge nette 67.9%. Le free cash flow a progressé à un CAGR de -0.5% sur 5 ans.
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $109.0M | $141.1M | $251.5M | $120.3M | $163.6M | $241.5M | $196.2M | $131.3M | $167.1M | $268.1M |
| Coût des Ventes | $5.6M | $5.4M | $6.3M | $11.3M | $30.4M | $62.2M | $52.8M | $35.0M | $11.1M | $6.6M |
| Marge Brute | $103.4M | $135.7M | $245.1M | $108.9M | $133.1M | $179.4M | $143.4M | $96.3M | $156.1M | $261.5M |
| R&D | $21.2M | $26.9M | $27.9M | $55.9M | $40.5M | $32.1M | $36.1M | $24.5M | $21.4M | $81.2M |
| Frais Généraux | $26.6M | $28.7M | $37.7M | $41.9M | $60.0M | $46.8M | $70.1M | $52.8M | $78.7M | $92.4M |
| Charges Opérationnelles | $58.5M | $67.7M | $81.4M | -$698.1M | $95.6M | $75.5M | $140.4M | $84.3M | $178.7M | $214.3M |
| Résultat Opérationnel | $43.9M | $68.1M | $163.7M | $807.1M | $37.5M | $103.9M | $3.0M | $11.9M | -$22.6M | $47.2M |
| EBITDA | $55.2M | $81.2M | $238.3M | $876.1M | $56.7M | $142.8M | $81.2M | $100.8M | $40.8M | $192.7M |
| Charges d'Intérêt | $12.2M | $11.4M | $48.3M | $35.7M | $27.4M | $19.6M | $1.8M | $656000 | $3.0M | $4.7M |
| Résultat Avant Impôts | $8.0M | $57.2M | $173.3M | $796.6M | $1.3M | $72.2M | $36.0M | $63.7M | $2.5M | $159.0M |
| Impôts | $10.3M | $44.7M | $30.0M | $167.3M | -$5.3M | -$4.1M | $41.2M | $9.8M | $6.5M | $34.5M |
| Résultat Net | -$1.6M | $12.6M | $143.3M | $629.3M | -$3.0M | $57.1M | -$33.4M | $52.2M | -$4.0M | $124.5M |
| BPA | $-0.08 | $0.60 | $5.96 | $33.13 | $-0.18 | $3.46 | $-1.98 | $3.02 | $-0.22 | $6.44 |
| BPA Dilué | $-0.08 | $0.53 | $5.96 | $31.85 | $-0.18 | $3.34 | $-1.98 | $2.94 | $-0.22 | $6.13 |
| Actions en Circulation (Diluées) | $20.8M | $23.5M | $24.1M | $19.8M | $16.2M | $17.2M | $16.9M | $17.8M | $18.3M | $20.3M |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $141.0M | $201.7M | $718.4M | $71.5M | $47.6M | $19.5M | $45.0M | $23.0M | $72.3M | $174.9M |
| Placements à Court Terme | 0 | 0 | $46.2M | $998.3M | $363.6M | $321.6M | $166.9M | $147.4M | $183.9M | $558.6M |
| Créances | $18.2M | $25.6M | $55.9M | $41.7M | $59.1M | $91.6M | $35.0M | $39.3M | $42.4M | $61.0M |
| Stocks | $1.9M | $4.4M | $7.1M | $7.3M | $26.5M | $27.3M | $13.3M | $24.0M | $14.1M | $9.1M |
| Actifs Courants | $163.1M | $237.0M | $870.5M | $1.12B | $500.6M | $464.8M | $263.6M | $237.4M | $331.6M | $832.3M |
| Immobilisations Corporelles | $1.8M | $4.2M | $5.4M | $17.6M | $37.2M | $32.6M | $27.5M | $25.1M | $24.8M | $10.8M |
| Goodwill | $276.9M | $314.5M | $306.4M | $95.2M | $189.7M | $105.7M | $105.7M | $103.4M | $105.2M | $101.5M |
| Actifs Incorporels | $25.8M | $19.5M | $31.5M | $230.5M | $606.3M | $386.8M | $352.6M | $299.6M | $266.6M | $422.3M |
| Actifs Totaux | $601.6M | $671.0M | $1.26B | $1.49B | $1.36B | $1.30B | $762.7M | $787.2M | $941.8M | $1.56B |
| Dettes Fournisseurs | $2.7M | $2.3M | $4.2M | $2.4M | $3.8M | $8.4M | $5.3M | $2.4M | $5.2M | $3.2M |
| Dette à Court Terme | $212.9M | $224.5M | $26.4M | 0 | 0 | 0 | $76.7M | 0 | 0 | 0 |
| Passifs Courants | $227.1M | $238.9M | $82.2M | $17.0M | $100.1M | $41.7M | $98.8M | $16.8M | $37.1M | $37.4M |
| Dette à Long Terme | $29.6M | $18.9M | $609.9M | $639.0M | $442.3M | $320.7M | 0 | 0 | 0 | $446.2M |
| Passifs Totaux | $230.7M | $252.4M | $699.9M | $727.7M | $652.8M | $476.4M | $165.2M | $86.3M | $111.3M | $543.4M |
| Réserves | -$431.1M | -$400.9M | -$229.2M | $400.1M | $392.0M | $449.1M | $450.9M | $503.0M | $499.0M | $608.1M |
| Capitaux Propres | $370.9M | $418.6M | $560.9M | $767.2M | $709.5M | $821.2M | $597.5M | $700.9M | $830.4M | $1.02B |
| Dette Totale | $212.9M | $224.5M | $636.3M | $650.2M | $456.4M | $324.4M | $87.7M | $6.2M | $7.1M | $451.5M |
| Dette Nette | $71.9M | $22.9M | -$128.3M | -$419.7M | $45.2M | -$16.7M | -$124.1M | -$164.1M | -$249.1M | -$282.0M |
| Fonds de Roulement | -$64.1M | -$1.8M | $788.3M | $1.11B | $400.4M | $423.1M | $164.8M | $220.6M | $294.4M | $794.8M |
Tableau de Flux (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Résultat Net | -$2.4M | $12.6M | $143.3M | $629.3M | -$3.0M | $57.1M | -$33.4M | $52.2M | -$4.0M | $124.5M |
| Amortissements | $11.3M | $11.7M | $14.7M | $43.7M | $28.0M | $50.9M | $51.4M | $36.5M | $35.2M | $35.7M |
| Stock-based Compensation | $18.9M | $24.9M | $20.8M | $24.5M | $30.7M | $38.8M | $60.3M | $25.7M | $41.1M | 0 |
| Variation du BFR | -$10.6M | -$11.4M | -$38.9M | -$4.2M | -$10.1M | -$52.2M | $65.7M | -$34.4M | $19.4M | -$12.7M |
| Cash Flow Opérationnel | $63.0M | $93.6M | $194.1M | -$29.3M | $54.6M | $78.8M | $137.8M | $49.6M | $97.0M | $49.4M |
| CapEx | -$28.3M | -$7.2M | -$11.9M | -$2.6M | -$4.5M | -$8.8M | -$17.9M | -$53.8M | -$19.6M | -$452000 |
| Acquisitions | -$94.2M | -$26.7M | -$5.9M | -$12.8M | -$383.3M | $494000 | -$750000 | -$25.7M | -$172.2M | -$8.1M |
| Rachat d'Actions | -$3.9M | -$2.0M | -$122.9M | -$453.0M | -$78.0M | -$18.4M | 0 | 0 | 0 | -$15.0M |
| Dividendes Payés | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | $34.7M | $86.4M | $182.2M | -$31.9M | $50.1M | $70.0M | $119.9M | -$4.3M | $77.4M | $48.9M |
Croissance et Marges (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Croissance Revenus (annuelle) | +29.5% | +78.2% | -52.2% | +36.0% | +47.7% | -18.8% | -33.1% | +27.3% | +60.4% | |
| Croissance Résultat Net (annuelle) | +867.5% | +1041.5% | +339.1% | -100.5% | +2014.2% | -158.4% | +256.3% | -107.7% | +3186.6% | |
| Croissance BPA (annuelle) | +864.3% | +893.3% | +455.9% | -100.5% | +2022.2% | -157.2% | +252.5% | -107.3% | +3027.3% | |
| Variation Actions (annuelle) | +12.7% | +2.5% | -17.9% | -18.1% | +6.6% | -2.2% | +5.3% | +3.0% | +11.0% | |
| Croissance FCF (annuelle) | +149.2% | +110.8% | -117.5% | +257.2% | +39.7% | +71.2% | -103.6% | +1912.0% | -36.8% | |
| Marge Brute | 94.9% | 96.2% | 97.5% | 90.6% | 81.4% | 74.3% | 73.1% | 73.3% | 93.4% | 97.5% |
| Marge Opérationnelle | 40.3% | 48.2% | 65.1% | 671.0% | 22.9% | 43.0% | 1.5% | 9.1% | -13.5% | 17.6% |
| Marge EBITDA | 50.6% | 57.5% | 94.8% | 728.4% | 34.6% | 59.1% | 41.4% | 76.8% | 24.4% | 71.9% |
| Marge Nette | -1.5% | 8.9% | 57.0% | 523.2% | -1.8% | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% |
| Marge FCF | 31.8% | 61.2% | 72.4% | -26.5% | 30.6% | 29.0% | 61.1% | -3.3% | 46.3% | 18.2% |
| Taux d'Imposition Effectif | 129.7% | 78.1% | 17.3% | 21.0% | -410.7% | -5.7% | 114.5% | 15.5% | 260.1% | 21.7% |
Données par Action (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF par Action | $1.66 | $3.68 | $7.57 | $-1.61 | $3.10 | $4.06 | $7.11 | $-0.24 | $4.23 | $2.41 |
| Dividende par Action | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Actions en Circulation (Basiques) | $20.8M | $21.0M | $24.0M | $19.0M | $16.2M | $16.6M | $16.9M | $17.3M | $18.3M | $19.3M |
Quoi regarder en Biotech
La plupart des petites biotechs perdent de l'argent. Les analyser avec le P/E n'a aucun sens — regardez cash et pipeline.
- Cash Runway — Mois de cash au rythme actuel. <18 mois = risque de dilution urgente
- Cash burn annuel — Rythme de consommation de cash opérationnel. À comparer à la position de cash
- Total Debt — Biotech sans revenus + dette = recette de faillite
- R&D / Capitalisation — Combien ils investissent dans le pipeline vs la valeur de l'entreprise — intensité R&D
- Capitalisation / Cash — S'il cote près de son cash, le marché donne ~0 valeur au pipeline — opportunité ou piège
Rentabilité
| Marge brute | 98.58% |
| Marge opérationnelle | 34.74% |
| Marge nette | 67.88% |
Santé financière
| Dette / Capitaux propres | 1.17 |
| Ratio de liquidité | 31.18 |
Ratios Clés (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| PER | -807.52 | 142.37 | 14.20 | 1.96 | -344.67 | 27.85 | -33.74 | 23.65 | -487.05 | 29.36 |
| P/B | 3.56 | 4.29 | 3.63 | 1.61 | 1.42 | 1.95 | 1.89 | 1.76 | 2.36 | 3.59 |
| P/V | 12.12 | 12.73 | 8.10 | 10.27 | 6.14 | 6.63 | 5.74 | 9.41 | 11.73 | 13.64 |
| Marge Brute | 94.9% | 96.2% | 97.5% | 90.6% | 81.4% | 74.3% | 73.1% | 73.3% | 93.4% | 97.5% |
| Marge Opérationnelle | 40.3% | 48.2% | 65.1% | 671.0% | 22.9% | 43.0% | 1.5% | 9.1% | -13.5% | 17.6% |
| Marge Nette | -1.5% | 8.9% | 57.0% | 523.2% | -1.8% | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% |
Entreprises liées: ACAD · ADMA · BLTE · CRNX · DYN · MIRM · NAMS
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de LGND: Vue d'ensemble · Valorisation · Statistiques · Estimations · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions